


CLAIMS:

1. A compound of formula (I):



5 or a pharmaceutically acceptable derivative thereof, wherein

R represents C₁₋₆alkyl (optionally substituted by C₁₋₆alkyloxy or Het), or C₁₋₆alkyloxy;

R¹ and R² independently represent hydrogen, halo or C₁₋₆alkyl;

ring A represents Het¹;

10 X represents O or NR³;

R³ represents hydrogen or C₁₋₆alkyl;

ring B represents a phenyl group or Het², either of which may be optionally substituted with one or more groups selected from halo, CN, C₁₋₆alkyloxy, CF₃, C₁₋₆alkyl, NH₂ and NO₂;

15 Het and Het¹ independently represent a 5- or 6-membered saturated, partially unsaturated or aromatic heterocyclic group comprising either (a) 1 to 4 nitrogen atoms, (b) one oxygen or one sulphur atom or (c) 1 oxygen atom or 1 sulphur atoms and 1 or 2 nitrogen atoms;

20 Het² represent a 5- or 6-membered aromatic heterocyclic group comprising either (a) 1 to 4 nitrogen atoms, (b) one oxygen or one sulphur atom or (c) 1 oxygen atom or 1 sulphur atoms and 1 or 2 nitrogen atoms.

2. A compound according to claim 1, wherein R represents methyl, methoxy; methoxymethyl or ethoxymethyl;

25

3. A compound according to claim 1, wherein R represents methylene-Het and Het represents triazolyl, morpholinyl or piperidinyl;

4. A compound according to claim 1 or claim 2, wherein R¹ represents chloro;

30

5. A compound according to any of claims 1 to 4, wherein R² represents hydrogen or methyl;

6. A compound according to any of claims 1 to 5, wherein ring A is attached to the triazole ring via a nitrogen atom;
7. A compound according to any of claims 1 to 6, wherein ring A represents
5 piperidinylene;
8. A compound according to any of claims 1 to 7, wherein X represents O;
9. A compound according to any of claims 1 to 7, wherein X represents NR^3 and R^3
10 represents H or Me;
10. A compound according to any of claims 1 to 9, wherein ring B represents phenyl, pyridinyl or pyrazinyl;
11. A compound according to any of claims 1 to 10, wherein ring B is mono- or di-
15 substituted,
12. A compound according to any of claims 1 to 11, wherein the substituent or substituents on ring B are independently selected from F, Cl, CN, methyl, methoxy, CF_3 ,
20 NO_2 , and CONH_2 ;
13. A compound according to claim 1 selected from:
1-[4-(4-Chloro-phenyl)-5-methyl-4H-[1,2,4]triazole-3-yl]-4-phenoxy-piperidine;
2-({1-[4-(4-Chlorophenyl)-5-(methoxymethyl)-4H-1,2,4-triazol-3-yl]piperidin-4-
25 yl}oxy)pyridine;
2-{1-[4-(4-Chloro-phenyl)-5-[1,2,3]triazole-2-yl)methyl-4H-[1,2,4]triazole-3-yl]-
piperidin-4-yloxy}-pyrimidine;
2-{1-[4-(4-Chloro-phenyl)-5-ethoxy-4H-[1,2,4]triazole-3-yl]-piperidin-4-yloxy}-
pyrimidine;
30 *N*-{1-[4-(4-Chlorophenyl)-5-methyl-4H-1,2,4-triazol-3-yl]-piperidin-4-yl}-*N*-
methylpyridin-2-amine; and
N-{1-[4-(4-Chlorophenyl)-5-methyl-4H-1,2,4-triazol-3-yl]-piperidin-4-yl}-*N*-
methylpyrimidin-2-amine
14. The use of a compound according to any of claims 1 to 13 as a medicament.
35

15. A method of treatment of a mammal, including a human being, to treat a disorder for which a V1a antagonist is indicated, comprising administering a therapeutically effective amount of a compound according to any of claims 1 to 13.
- 5 16. A method of treatment of a mammal, including a human being, to treat anxiety, cardiovascular disease (including angina, atherosclerosis, hypertension, heart failure, edema, hypernatremia), dysmenorrhoea (primary and secondary), endometriosis, emesis (including motion sickness), intrauterine growth retardation, inflammation (including rheumatoid arthritis), mittlemerchz, preclampsia, premature ejaculation, 10 premature (preterm) labour or Raynaud's disease, comprising administering a therapeutically effective amount of a compound according to any of claims 1 to 13 to a patient suffering from such a disorder.
17. A method of treatment according to claim 15 or claim 16, wherein the disorder is 15 dysmenorrhoea (primary or secondary).
18. Use of a compound according to any of claims 1 to 13 in the manufacture of a medicament for the treatment of a disorder for which a V1a receptor antagonist is indicated. 20
19. Use of a compound according to any of claims 1 to 13 in the manufacture of a medicament for the treatment of anxiety, cardiovascular disease (including angina, atherosclerosis, hypertension, heart failure, edema, hypernatremia), dysmenorrhoea (primary and secondary), endometriosis, emesis (including motion sickness), intrauterine 25 growth retardation, inflammation (including rheumatoid arthritis), mittlemerchz, preclampsia, premature ejaculation, premature (preterm) labour or Raynaud's disease.
20. Use according to claim 18 or claim 19, wherein the disorder is dysmenorrhoea (primary or secondary). 30
21. A pharmaceutical formulation including a compound according to any of claims 1 to 13, together with a pharmaceutically acceptable excipient, diluent or carrier.
22. A combination of (A) a compound according to any of claims 1 to 13, and (B) 35 another pharmacologically active ingredient.

23. A combination according to claim 22, wherein (B) is an oral contraceptive, PDEV inhibitor, COX inhibitor, NO-donor or L-arginine.

24. Use of a combination according to claim 22 or claim 23, for the manufacture of a
5 medicament for combination therapy by simultaneous, sequential or separate administration, in the treatment of dysmenorrhoea.

25. A method of treating dysmenorrhoea comprising administering to a subject in need of such treatment a combination of amounts of (A) and (B) according to claim 22 or
10 claim 23, which are together effective.

26. A pharmaceutical product containing a combination of (A) and (B) according to claim 22 or claim 23, as a combined preparation for simultaneous, separate or sequential use in treating dysmenorrhoea (Primary or secondary).
15